Ipca Laboratories Limited (IPCALAB.BO)
INR 1378.45
(-1.3%)
INR 1378.45
(-1.3%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 76.22 Billion INR | 24.14% |
| 2022 | 62.06 Billion INR | 7.64% |
| 2021 | 57.66 Billion INR | 7.46% |
| 2020 | 53.66 Billion INR | 17.71% |
| 2019 | 45.58 Billion INR | 23.47% |
| 2018 | 36.92 Billion INR | 15.14% |
| 2017 | 32.06 Billion INR | 3.66% |
| 2016 | 30.93 Billion INR | 7.86% |
| 2015 | 28.68 Billion INR | -7.98% |
| 2014 | 31.16 Billion INR | -4.02% |
| 2013 | 32.46 Billion INR | 16.75% |
| 2012 | 27.81 Billion INR | 19.34% |
| 2011 | 23.3 Billion INR | 22.67% |
| 2010 | 18.99 Billion INR | 21.82% |
| 2009 | 15.59 Billion INR | 21.48% |
| 2008 | 12.83 Billion INR | 22.12% |
| 2007 | 10.51 Billion INR | 13.25% |
| 2006 | 9.28 Billion INR | 22.21% |
| 2005 | 7.59 Billion INR | 11.86% |
| 2004 | 6.79 Billion INR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 20.92 Billion INR | 2.93% |
| 2023 Q2 | 20.33 Billion INR | 28.12% |
| 2023 Q1 | 15.87 Billion INR | 7.69% |
| 2023 FY | 77.05 Billion INR | 24.14% |
| 2023 Q3 | 20.52 Billion INR | 0.93% |
| 2023 Q4 | 20.33 Billion INR | -0.97% |
| 2022 Q1 | 15.85 Billion INR | 29.37% |
| 2022 Q3 | 15.46 Billion INR | -3.43% |
| 2022 Q4 | 14.74 Billion INR | -4.65% |
| 2022 Q2 | 16 Billion INR | 0.96% |
| 2022 FY | 62.06 Billion INR | 7.64% |
| 2021 FY | 57.66 Billion INR | 7.46% |
| 2021 Q2 | 15.44 Billion INR | -1.36% |
| 2021 Q3 | 14.3 Billion INR | -7.38% |
| 2021 Q4 | 12.25 Billion INR | -14.31% |
| 2021 Q1 | 15.65 Billion INR | 51.19% |
| 2020 FY | 53.66 Billion INR | 17.71% |
| 2020 Q4 | 10.35 Billion INR | -26.54% |
| 2020 Q3 | 14.09 Billion INR | 3.58% |
| 2020 Q2 | 13.61 Billion INR | -11.29% |
| 2020 Q1 | 15.34 Billion INR | 55.97% |
| 2019 FY | 45.58 Billion INR | 23.47% |
| 2019 Q3 | 12.12 Billion INR | -5.53% |
| 2019 Q4 | 9.83 Billion INR | -18.89% |
| 2019 Q1 | 10.78 Billion INR | 35.01% |
| 2019 Q2 | 12.83 Billion INR | 19.08% |
| 2018 Q2 | 10.12 Billion INR | 15.6% |
| 2018 FY | 36.92 Billion INR | 15.14% |
| 2018 Q4 | 7.98 Billion INR | -20.63% |
| 2018 Q3 | 10.06 Billion INR | -0.58% |
| 2018 Q1 | 8.75 Billion INR | 0.0% |
| 2017 FY | 32.06 Billion INR | 3.66% |
| 2016 FY | 30.93 Billion INR | 7.86% |
| 2015 FY | 28.68 Billion INR | -7.98% |
| 2014 FY | 31.16 Billion INR | -4.02% |
| 2013 FY | 32.46 Billion INR | 16.75% |
| 2012 FY | 27.81 Billion INR | 19.34% |
| 2011 FY | 23.3 Billion INR | 22.67% |
| 2010 FY | 18.99 Billion INR | 21.82% |
| 2009 FY | 15.59 Billion INR | 21.48% |
| 2008 FY | 12.83 Billion INR | 22.12% |
| 2007 FY | 10.51 Billion INR | 13.25% |
| 2006 FY | 9.28 Billion INR | 22.21% |
| 2005 FY | 7.59 Billion INR | 11.86% |
| 2004 FY | 6.79 Billion INR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Alkem Laboratories Limited | 126.67 Billion INR | 39.827% |
| Amrutanjan Health Care Limited | 4.21 Billion INR | -1709.558% |
| Alembic Pharmaceuticals Limited | 61.12 Billion INR | -24.71% |
| AstraZeneca Pharma India Limited | 12.95 Billion INR | -488.362% |
| Aurobindo Pharma Limited | 287.04 Billion INR | 73.445% |
| Biofil Chemicals and Pharmaceuticals Limited | 400.35 Million INR | -18939.223% |
| Eris Lifesciences Limited | 20.09 Billion INR | -279.386% |
| FDC Limited | 19.42 Billion INR | -292.312% |
| Glenmark Life Sciences Limited | 22.83 Billion INR | -233.846% |
| Jagsonpal Pharmaceuticals Limited | 2.08 Billion INR | -3552.294% |
| Krebs Biochemicals & Industries Limited | 504.21 Million INR | -15017.38% |
| Laurus Labs Limited | 50.01 Billion INR | -52.393% |
| Lupin Limited | 200.1 Billion INR | 61.909% |
| Medicamen Biotech Limited | 1.79 Billion INR | -4151.058% |
| Medico Remedies Limited | 1.44 Billion INR | -5159.711% |
| Megasoft Limited | 373.95 Million INR | -20283.337% |
| NATCO Pharma Limited | 40.02 Billion INR | -90.465% |
| Piramal Pharma Limited | 81.71 Billion INR | 6.716% |
| Sigachi Industries Limited | 3.98 Billion INR | -1810.589% |
| Solara Active Pharma Sciences Limited | 12.38 Billion INR | -515.51% |
| Sun Pharmaceutical Industries Limited | 484.96 Billion INR | 84.283% |
| Suven Pharmaceuticals Limited | 10.51 Billion INR | -625.009% |
| Syncom Formulations (India) Limited | 2.59 Billion INR | -2840.245% |
| Themis Medicare Limited | 3.81 Billion INR | -1896.646% |
| Torrent Pharmaceuticals Limited | 106.05 Billion INR | 28.127% |
| Valiant Laboratories Limited | 1.82 Billion INR | -4086.822% |
| Wanbury Limited | 5.75 Billion INR | -1224.14% |
| Windlas Biotech Limited | 6.3 Billion INR | -1108.073% |
| ZIM Laboratories Limited | 3.67 Billion INR | -1974.552% |
| Zydus Lifesciences Limited | 190.21 Billion INR | 59.927% |
| Ajanta Pharma Limited | 42.08 Billion INR | -81.11% |
| Ind-Swift Laboratories Limited | 12.8 Billion INR | -495.082% |
| Achyut Healthcare Limited | 61.36 Million INR | -124106.195% |
| Lasa Supergenerics Limited | 1.04 Billion INR | -7205.708% |
| Sun Pharma Advanced Research Company Limited | 755.45 Million INR | -9989.853% |
| Aarti Pharmalabs Limited | 18.15 Billion INR | -319.851% |
| Alpa Laboratories Limited | 1.08 Billion INR | -6909.822% |
| Gufic Biosciences Limited | 8.06 Billion INR | -844.928% |
| Ind-Swift Limited | 5.02 Billion INR | -1416.994% |
| Indoco Remedies Limited | 17.89 Billion INR | -325.964% |
| Hester Biosciences Limited | 3.04 Billion INR | -2402.876% |
| Bliss GVS Pharma Limited | 7.7 Billion INR | -889.609% |
| Bajaj HealthCare Limited | 4.73 Billion INR | -1510.081% |
| RPG Life Sciences Limited | 5.82 Billion INR | -1209.58% |
| Mankind Pharma Limited | 103.34 Billion INR | 26.245% |
| Glenmark Pharmaceuticals Limited | 118.13 Billion INR | 35.475% |
| Unichem Laboratories Limited | 16.57 Billion INR | -359.897% |
| Bal Pharma Limited | 3.39 Billion INR | -2147.043% |
| Strides Pharma Science Limited | 40.51 Billion INR | -88.155% |
| Venus Remedies Limited | 5.91 Billion INR | -1188.767% |
| Jubilant Pharmova Limited | 67.02 Billion INR | -13.718% |
| Dr. Reddy's Laboratories Limited | 279.16 Billion INR | 72.696% |
| Divi's Laboratories Limited | 78.45 Billion INR | 2.837% |
| Nectar Lifesciences Limited | 16.84 Billion INR | -352.614% |
| Shilpa Medicare Limited | 11.51 Billion INR | -561.896% |
| Aarti Drugs Limited | 25.28 Billion INR | -201.451% |
| IOL Chemicals and Pharmaceuticals Limited | 21.18 Billion INR | -259.724% |
| Suven Life Sciences Limited | 116.92 Million INR | -65088.362% |
| J. B. Chemicals & Pharmaceuticals Limited | 34.84 Billion INR | -118.772% |
| Hikal Limited | 17.84 Billion INR | -327.121% |
| Procter & Gamble Health Limited | 11.51 Billion INR | -562.093% |
| Sequent Scientific Limited | 13.69 Billion INR | -456.49% |
| Novartis India Limited | 3.35 Billion INR | -2174.871% |
| Granules India Limited | 45.06 Billion INR | -69.148% |
| Wockhardt Limited | 27.89 Billion INR | -173.303% |
| Brooks Laboratories Limited | 794.86 Million INR | -9489.614% |
| Neuland Laboratories Limited | 15.58 Billion INR | -389.061% |
| Morepen Laboratories Limited | 17.01 Billion INR | -347.877% |
| Kilitch Drugs (India) Limited | 1.54 Billion INR | -4837.673% |
| Mangalam Drugs & Organics Limited | 3.68 Billion INR | -1967.965% |